Table 3.
RAAS peptides among patients with and without COVID-19. Data are presented as mean ± s.d.
| No COVID-19 (n = 43) | COVID-19 (n = 43) | Relative between-group difference (95% CI) | |
|---|---|---|---|
| RAAS peptides, pmol/L | |||
| Angiotensin I | 66.8 ± 6.8 | 31.6 ± 5.7 | –52.7% (–68.5 to –36.9) |
| Angiotensin II | 92.5 ± 6.4 | 37.7 ± 4.9 | –59.2% (–72.1 to –46.3) |
| Angiotensin (1–5) | 6.6 ± 3.4 | 3.3 ± 2.2 | –49.7% (–59.2 to –40.2) |
| Angiotensin (1–7) | 7.6 ± 4.7 | 4.8 ± 2.9 | –64.9% (–84.5 to –45.3) |
| Enzymatic activity, pmol/L | |||
| Plasma renin activity | 207.9 ± 5.5 | 88.6 ± 4.5 | –58.5% (–71.4 to –45.6) |
| Plasma ACE activity | 1.9 ± 2.9 | 1.8 ± 2.2 | –5.2% (–22.3 to 11.8) |
| Plasma ACE2 activity | 0.07 ± 0.3 | 0.09 ± 0.3 | 23.2% (–2.80 to 49.25) |
ACE, angiotensin-converting enzyme; RAAS, renin-angiotensin-aldosterone system.